Condor selects Cirium as its strategic partner for aviation analytics
Cirium is now Condor's new partner for aviation analytics, with the new agreement making Cirium the airline’s single source of external aviation data, providing end-to-end data services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903082962/en/
Condor A330neo (Photo: Business Wire)
The partnership between Cirium, the aviation analytics firm, and Condor, will empower the German carrier to further improve its operations, driving quality insights aimed at improving the businesses efficiency and overall customer satisfaction.
As part of this new agreement, Cirium will provide the airline with three key data sets: historical flight data, schedules data, and real-time flight data.
Having utilised Cirium's historical flight data for two years, Condor's decision to now integrate Cirium’s additional suite of products presents a unique opportunity to further streamline operations, driving direct improvements for both the business and its customers.
This investment in data will enable the business to swiftly identify operational trends, allowing for quick solutions that reduce costs and enhance efficiency. It will empower teams to optimise fleet management, network planning, connections, and crew scheduling, driving significant improvements across all aspects of operations.
Cirium’s highly regarded flight schedules product is also part of the deal, offering deeper insights into service opportunities and market demand. With the up-to-date data, Condor will be able to optimise network and crew planning, boosting efficiency and profitability across the business.
The addition of Cirium’s real-time flight data will also provide live updates on aircraft around the world, meaning flights can be tracked and monitored with greater detail.
This will support Condor’s investment in its customer experience proposition, with Cirium’s live flight data feeding directly into customer-facing digital platforms, giving travellers precise departure and arrival times so they can plan their onward journeys. The addition of real-time flight data will also transform disruption management, offering even faster rebooking options to those with missed connections.
Jeremy Bowen, Cirium CEO, said: “We are very excited to announce this expanded collaboration with Condor, a leading global leisure airline. Condor has been a client of Cirium, benefiting from our historical flight data, and this strengthened partnership is a testament to both the quality of our data and the dedication of the Cirium team. Through this extended relationship, we will provide Condor with the most precise and reliable industry data, helping them enhance operational performance and, most importantly, deliver timely insights to their passengers worldwide.”
As Germany's most popular leisure airline, Condor has been flying customers to the world’s most beautiful destinations since 1956. With a fleet of over 50 aircraft, the airline serves around 90 destinations from Germany and Switzerland. This partnership with Cirium marks the latest step in Condor’s ongoing commitment to operational excellence and customer satisfaction.
Cirium is the world’s most trusted source of aviation analytics, delivering powerful data and cutting-edge analytics to empower a wide spectrum of industry players.
Equipping airlines, airports, travel enterprises, aircraft manufacturers, and financial entities, the company provides the clarity and intelligence needed to optimise operations, make informed decisions and accelerate revenue growth.
To learn more about Cirium’s products, and how they can benefit your business, visit www.cirium.com
About Condor
As Germany's most popular leisure airline, Condor has been taking its guests to the world's most beautiful holiday destinations since 1956. Condor operates a fleet of over 50 aircraft, which are maintained by the company's own maintenance operation, Condor Technik GmbH, according to the highest safety standards at the Frankfurt and Dusseldorf locations. In spring 2022, Germany's most popular leisure airline unveiled its new brand identity. This illustrates the development from a leisure airline to a unique and unmistakable vacation brand. The new design was unveiled with the first A330neo, which has been operated by Condor since December 2022. As the German launch customer, Condor will then be flying 21 A330neo long-haul aircraft. Thanks to state-of-the-art technology and maximum efficiency, the latest-generation 2-liter aircraft is the European front-runner with 2.1 liters per passenger per 100 kilometers and maximum customer comfort. Condor will also receive 43 brand-new short- and medium-haul aircraft of the A32Xneo family from 2024.
About Cirium
Cirium® is the world’s most trusted source of aviation analytics, delivering powerful data and cutting-edge analytics to empower a wide spectrum of industry players. Equipping airlines, airports, travel enterprises, aircraft manufacturers, and financial entities, the company provides the clarity and intelligence needed to optimise operations, make informed decisions and accelerate revenue growth.
Cirium® is part of LexisNexis® Risk Solutions, a RELX business, which provides information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
To learn more about Cirium’s products, and how they can benefit your business, visit www.cirium.com, and follow Cirium on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903082962/en/
Contacts
For Cirium media inquiries please contact media@cirium.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom